At screening, the mean duration of diabetes was approximately 12 years, the mean BMI was approximately 31 kg/m2, mean eGFR was 80.6 mL/min/1.73 m2 and 86.1% of patients had an eGFR 60 mL/min
In: Vitamins and Hormones
Mean body-weight loss from each drugs pivotal Phase 3 trial (SCALE for liraglutide 3.0 mg
Back to Journals Diabetes, Metabolic Syndrome and Obesity Volume 19 GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists Authors Abid M, Sheikh KS, Ahmad MS, Jiang H Received 19 January 2026 Accepted for publication 17 March 2026 Published 12 June 2026 Volume 2026:19 566414 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Donald McClain Mahroz Abid, 1 Khizer Sohail Sheikh, 1 Muhammad Shahbaz Ahmad, 2 Hongwei Jiang 1 1 Department of Metabolism and Endocrinology, Endocrine and Metabolic Disease Center, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Peoples Republic of China
Metabol-Clin Exp (1999) 48:3859
The total number of GLP-1 users is expected to increase significantly over the coming years as pharma expands production capacity, reduces prices, develops new products with fewer side effects, and offers more user-friendly dosage forms
